CDK4 and breast carcinoma: Likewise, in another phase I/II trial (NCT04553133), the novel CDK2i PF-07104091 showed clinical efficacy in a previously largely treated advanced/relapsed breast cancer population progressing during ET plus CDK4/6is [184].